Results demonstrated that SGLT2 inhibitors have a neutral effect on the risk of stroke and its subtypes (fatal stroke, non-fatal stroke, ischemic stroke, or transient ischemic attack), but a potential protective effect against hemorrhagic stroke was associated with SGLT2 inhibitors a significant 50% reduction compared with placebo (RR = 0.49, 95% CI 0.30–0.82, p = 0.007) [183]. Here, SLC5A2 is linked to transient ischemic attack.